CN121794754A - 信息处理装置、信息处理装置的运行方法及信息处理装置的运行程序 - Google Patents

信息处理装置、信息处理装置的运行方法及信息处理装置的运行程序

Info

Publication number
CN121794754A
CN121794754A CN202480055463.XA CN202480055463A CN121794754A CN 121794754 A CN121794754 A CN 121794754A CN 202480055463 A CN202480055463 A CN 202480055463A CN 121794754 A CN121794754 A CN 121794754A
Authority
CN
China
Prior art keywords
information
amino acid
information processing
acid sequence
processing apparatus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202480055463.XA
Other languages
English (en)
Chinese (zh)
Inventor
茑冈拓也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of CN121794754A publication Critical patent/CN121794754A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Health & Medical Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Chemical & Material Sciences (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Peptides Or Proteins (AREA)
CN202480055463.XA 2023-09-28 2024-09-12 信息处理装置、信息处理装置的运行方法及信息处理装置的运行程序 Pending CN121794754A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023-167582 2023-09-28
JP2023167582 2023-09-28
PCT/JP2024/032771 WO2025070104A1 (ja) 2023-09-28 2024-09-12 情報処理装置、情報処理装置の作動方法、および情報処理装置の作動プログラム

Publications (1)

Publication Number Publication Date
CN121794754A true CN121794754A (zh) 2026-04-03

Family

ID=95204085

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202480055463.XA Pending CN121794754A (zh) 2023-09-28 2024-09-12 信息处理装置、信息处理装置的运行方法及信息处理装置的运行程序

Country Status (5)

Country Link
US (1) US20260196292A1 (cg-RX-API-DMAC7.html)
EP (1) EP4760727A1 (cg-RX-API-DMAC7.html)
JP (1) JPWO2025070104A1 (cg-RX-API-DMAC7.html)
CN (1) CN121794754A (cg-RX-API-DMAC7.html)
WO (1) WO2025070104A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7236253B2 (ja) * 2018-11-07 2023-03-09 合同会社H.U.グループ中央研究所 情報処理方法および学習モデル
US20220157403A1 (en) * 2019-04-09 2022-05-19 Eth Zurich Systems and methods to classify antibodies
JP2021158973A (ja) 2020-03-31 2021-10-11 株式会社豊田中央研究所 変異体の熱的安定性を予測するためのモデル及びその利用

Also Published As

Publication number Publication date
JPWO2025070104A1 (cg-RX-API-DMAC7.html) 2025-04-03
WO2025070104A1 (ja) 2025-04-03
US20260196292A1 (en) 2026-07-09
EP4760727A1 (en) 2026-06-17

Similar Documents

Publication Publication Date Title
Piccoli et al. 2019 White paper on recent issues in bioanalysis: FDA immunogenicity guidance, gene therapy, critical reagents, biomarkers and flow cytometry validation (part 3–recommendations on 2019 FDA immunogenicity guidance, gene therapy bioanalytical challenges, strategies for critical reagent management, biomarker assay validation, flow cytometry validation & CLSI H62)
Chinery et al. Paragraph—antibody paratope prediction using graph neural networks with minimal feature vectors
Whitelegg et al. WAM: an improved algorithm for modelling antibodies on the WEB
Choi et al. Predicting antibody complementarity determining region structures without classification
Weitzner et al. Accurate structure prediction of CDR H3 loops enabled by a novel structure-based C-terminal constraint
Horvath et al. The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event?
Goel et al. Biosimilars in rheumatology: understanding the rigor of their development
Kurki et al. Biosimilar regulation in the EU
Thrift et al. Graph-pMHC: graph neural network approach to MHC class II peptide presentation and antibody immunogenicity
Quarmby et al. MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena
Nishigami et al. Revisiting antibody modeling assessment for CDR-H3 loop
Shakhnovich et al. Immunogenicity in clinical practice and drug development: when is it significant?
Barnett et al. Seroprevalence of measles, rubella, and varicella in refugees
Pelkmans et al. Antibodies against domain I of β2-glycoprotein I: the one and only?
US20250068803A1 (en) Pharmaceutical support device, operation method of pharmaceutical support device, and operation program of pharmaceutical support device
Sheridan Pharma consolidates its grip on post-antibody landscape.
Sullivan et al. Analytic characterization of biosimilars
Clarke et al. Patients with core antibody positive and surface antigen negative hepatitis B (anti-HBc+, HBsAg−) on anti-TNF therapy have a low rate of reactivation
Asor et al. Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition
Herling et al. Nonspecificity fingerprints for clinical-stage antibodies in solution
Gilep et al. Improving AlphaFold 3 structural modeling by incorporating explicit crosslinks
Tickle et al. High-throughput screening for high affinity antibodies
Carrasco-Triguero Insights on the immunogenicity of antibody–drug conjugates
Brown et al. De-risking clinical trial failure through mechanistic simulation
Perry et al. The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination